Chronic pain affects millions of people worldwide and remains one of the most common reasons for medical treatment. For decades, opioids were widely prescribed for moderate to severe pain. While effective in the short term, opioids carry a high risk of tolerance, dependence, respiratory depression, and overdose. As the opioid crisis intensified, researchers and policymakers began exploring alternative pain management strategies — including cannabis.
The comparison between cannabis and opioids centers on effectiveness, safety, addiction potential, and long-term outcomes.
How Opioids Work
Opioids such as morphine, oxycodone, and fentanyl bind to mu-opioid receptors in the brain and spinal cord. These receptors reduce the perception of pain but also depress the central nervous system. This mechanism explains both their strong analgesic properties and their dangerous side effects.
Long-term opioid use is associated with tolerance (requiring higher doses for the same effect), physical dependence, opioid use disorder, constipation, hormonal disruption, and risk of fatal overdose due to respiratory suppression.
According to data from the U.S. Centers for Disease Control and Prevention (CDC), opioid overdoses have caused hundreds of thousands of deaths in the United States over the past two decades.
How Cannabis Works for Pain
Cannabis interacts with the endocannabinoid system through CB1 and CB2 receptors. CB1 receptors influence pain perception in the brain and nervous system, while CB2 receptors are involved in immune and inflammatory responses.
THC (tetrahydrocannabinol) can alter pain signaling and produce analgesic effects. CBD (cannabidiol) may reduce inflammation and modulate immune responses. Unlike opioids, cannabinoids do not significantly suppress respiratory function, which dramatically lowers overdose risk.
A 2017 report from the National Academies of Sciences concluded there is “substantial evidence” that cannabis is effective for chronic pain in adults.
Effectiveness: What the Research Shows
A 2015 systematic review published in JAMA analyzed 28 randomized clinical trials and found moderate-quality evidence supporting cannabinoids for chronic neuropathic pain. While the magnitude of pain relief was modest, results were comparable to some opioid treatments for certain pain types.
In cancer-related pain, a 2010 randomized controlled trial published in The Journal of Pain found that a THC/CBD combination spray significantly improved pain scores compared to placebo in patients who did not achieve adequate relief from opioids alone.
Opioids remain more potent for acute and severe pain, such as post-surgical or trauma-related pain. However, for chronic non-cancer pain, long-term opioid therapy has shown diminishing benefits and increasing risks.
A 2018 study in JAMA Network Open found that long-term opioid therapy for chronic pain did not result in better pain-related function over 12 months compared to non-opioid medications.
Cannabis and Opioid Reduction
One of the most studied aspects of cannabis is its potential “opioid-sparing” effect. This refers to reducing opioid dosage when cannabis is used concurrently.
A 2014 study published in JAMA Internal Medicine found that states with medical cannabis laws had significantly lower opioid overdose mortality rates compared to states without such laws during the study period. While this does not prove causation, it suggests a possible association.
Additionally, patient surveys have reported that many individuals reduce or discontinue opioid use after initiating medical cannabis therapy. A 2017 study in Pain Medicine found that 64% of chronic pain patients reported decreased opioid use after starting cannabis.
More recent research has produced mixed results, indicating the relationship may be complex and influenced by social, regulatory, and healthcare factors.
Addiction and Dependence
Opioids carry a well-documented risk of opioid use disorder. Even short-term prescriptions can lead to dependence in some individuals.
Cannabis can also lead to cannabis use disorder, but the addiction risk appears significantly lower. Estimates suggest approximately 8–10% of cannabis users develop problematic use patterns, compared to a substantially higher risk with opioids.
Importantly, opioid overdose can be fatal due to respiratory depression. Cannabis does not typically cause lethal respiratory suppression, and there are no documented fatal overdoses from cannabis alone.
Side Effects and Safety
Common opioid side effects include constipation, nausea, sedation, hormonal suppression, and respiratory depression. Long-term use increases overdose risk and may worsen pain sensitivity (opioid-induced hyperalgesia).
Cannabis side effects may include dizziness, cognitive impairment, anxiety (particularly with high-THC products), dry mouth, and short-term memory changes. While these effects can impair functioning, they are generally not life-threatening.
However, cannabis may not be appropriate for everyone, especially individuals with a history of psychotic disorders or certain cardiovascular conditions.
Limitations of Current Research
Although cannabis shows promise as an alternative or adjunct to opioids, research gaps remain. Many cannabis studies are short-term, use varying formulations, and lack standardized dosing. Opioids have decades of clinical data, whereas large-scale long-term cannabis trials are still limited.
Additionally, cannabis may not adequately treat severe acute pain on its own. For certain conditions — such as major surgery or advanced cancer — opioids remain essential.
The Bottom Line
Opioids are powerful pain relievers but carry significant risks, including addiction and fatal overdose. Cannabis appears to offer moderate pain relief with a substantially lower risk of lethal overdose and may help reduce opioid use in some patients.
While cannabis is not a universal replacement for opioids, it may serve as a safer alternative or complementary therapy for certain types of chronic pain. Decisions regarding pain management should involve careful medical evaluation, individualized risk assessment, and consideration of both short-term effectiveness and long-term safety.
